“Gross business awards increased 11% on a sequential basis over quarter 1 with notable wins from several biotech customers as well as the continued ramp‑up of several large pharma partnerships.” （CEO）
“While study delays and the elongation of timelines from contracting to start date have presented a headwind… we are focused on improving cycle times and ultimately increase burn rate.” （CEO）
“We updated our full year guidance to reflect our expectation of higher pass‑through revenue this year, including the restart of next‑generation COVID vaccine trial.” （CEO）
“Revenue in quarter 2 was $2.017 billion, representing a year‑on‑year decrease of 4.8%. Revenue was up approximately 1% sequentially.” （CFO）
“We made significant share repurchases in quarter 2, totaling $250 million at an average price of $146 per share. We plan to remain active in buying back shares.” （CFO）
Prepared Metrics
Metric
Value
Speaker/Context
Revenue (Q2 2025)
$2,017M
CFO – Q2 revenue
Adjusted Gross Margin
28.3%
CFO – Q2, up 10bps QoQ
Adjusted EBITDA
$396M
CFO – Q2, up $5.4M QoQ
Adjusted EBITDA Margin
19.6%
CFO – Q2
Adjusted EPS
$3.26
CFO – Q2, down 13.1% YoY
Free Cash Flow
$113.9M
CFO – Q2
Net Book‑to‑Bill
1.02x
CEO – Q2, net of elevated cancellations
Share Repurchases (Q2)
$250M
CFO – avg price $146
Net Debt / Adj. EBITDA (TTM)
1.9x
CFO – Jun 30, 2025
FY2025 Revenue Guidance
$7.85B – $8.15B
CEO/CFO – midpoint $8.0B
FY2025 Adj. EPS Guidance
$13.50 (midpoint)
CEO/CFO – unchanged
Q&A Batch (1-5 of 13)
Q1 — Elizabeth Hammell Anderson
Topic: Demand inflection by market segment (biotech vs. pharma)
Key points:
RFP volume saw a modest mid-single-digit uptick, more in biotech than large pharma.
Early phase and Phase III business are looking positive.
Partnerships secured over last 18–24 months are being leveraged, with wins expanding within those partnerships.
Mgmt stance: Neutral – environment is "reasonably constructive" but volatile quarter-to-quarter; trailing 12-month basis shows positive trend.
Q2 — Michael Aaron Cherny
Topic: Biotech awards vs. funding environment
Key points:
3 of the top 4 awards in the quarter were in the biotech segment.
Decision-making times remain cautious; biotech funding environment shows a lag.
Large pharma is also contributing via partnership expansions.
Mgmt stance: Cautious – "not declaring victory"; progress is encouraging but volatile, waiting to see continued biotech improvement.
Q3 — Patrick Bernard Donnelly
Topic: Bookings trends, cancellations, and macro noise (tariffs, MFN)
Key points:
Gross bookings improved 10% over the previous quarter.
Cancellations expected to remain elevated in the short term.
Pharma sponsors are digesting bad news; positives include early FDA review, reduced animal testing, potential U.S. R&D tax benefits.
Mgmt stance: Constructive but cautious – environment is "settling down" but still volatile and uncertain; not yet through everything.
Q4 — David Howard Windley
Topic: Partnership expansion and down-market replication
Key points:
Competitive intensity has intensified over the last 3–6 months.
One partnership example: customer pivoted from a smaller full-service component to a blended full-service model, expanding ICLR’s wallet share.
Strategy to broaden partnerships from top 25 to companies in the 20–60 range, moving from transactional to deeper portfolio relationships.
Mgmt stance: Bullish – encouraged by progress; scale advantage in covering all outsourcing areas; successful in both large and midsized segments.
Q5 — Justin D. Bowers
Topic: Pipeline opportunities by therapy and phase
Key points:
Oncology remains the main driver of backlog and new wins.
Uptick in cardiovascular/metabolism (obesity, MASH, NASH) indications.
COVID vaccine work remains at 1%–2% of backlog and revenue.
Early phase and Phase III are both moving forward.
Mgmt stance: Constructive – "nice progress" over the last quarter; long-term opportunity encouraged by customer focus on both early and late-stage assets.
Q&A Batch (6-10 of 10)
Q6 — Jack Meehan
Topic: Industry share dynamics and win rates
Key points:
Gross wins were broad-based across customer segments; biotech segment showing progress.
FSP business continues to grow; early phase business made nice progress; lab business growing in the teens.
Gains indicated in functional, full-service, preclinical, labs, early phase, and imaging.
Mgmt stance: Neutral constructive — sees share gains but acknowledges market data is variable and volatile, not getting too far ahead.
Q7 — Eric White Coldwell
Topic: Cancellation levels and pass-through revenue trends
Key points:
Cancellations were $916 million; expects broadly similar number in near term before potential attenuation in Q4.
Therapeutic mix, especially cardiometabolic uptick, is the #1 driver of higher pass-through revenue.
No other underlying trends identified besides mix changes.
Mgmt stance: Neutral on cancellations (expect sustained elevated levels near term); neutral on pass-through (driven by mix, not inflation).
Q8 — Jailendra P. Singh
Topic: Pricing environment in large pharma and EBP segments
Key points:
Pricing environment has intensified a bit more recently; customers expect more value due to patent cliffs.
Competition is always present but has notched up; company aims to create value through cost efficiency and competitive pricing.
Key metric remains higher confidence in time, cost, and predictability of trial execution.
Mgmt stance: Neutral to cautious — acknowledges more intense pricing but sees opportunity to win through value proposition and incumbency.
Q9 — Luke England Sergott
Topic: Sustainability of metabolic trial boom and biotech demand
Key points:
Metabolic/obesity seen as long-term trend with large-scale, faster-burning trials; also MASH and CVT are active.
Biotech funding does not fully support the observed uptick; win rate in that segment is improving.
Volatile environment; no single pivot point in the quarter; qualitative assessment shows encouraging opportunities.
Mgmt stance: Constructive but cautious — sees long-term opportunity but acknowledges possible slowdown and not out of the woods yet.
Q10 — Maxwell Andrew Smock
Topic: Burn rate guidance and second-half outlook
Key points:
Midpoint of guide implies ~20 bps step-down in H2; management expects burn rate broadly stable year-round at ~8% for full year.
Step-up in revenue guide is driven by increased pass-throughs, not a change in burn rate assumptions.
Book-to-bill expected at roughly same level through rest of year.
Mgmt stance: Neutral — burn rate stable, guide reflects same underlying assumptions as April.
Q&A Batch (11-13 of 13)
Q11 — Charles Rhyee
Topic: Cancellations, book-to-bill, and FX impact on revenue guidance
Key points:
Q3 cancellations expected in same "post code" as Q2 (~$900M+), but Q2 included a $300M BARDA COVID trial cancel; mgmt says BARDA is not an exceptional item for Q3.
Book-to-bill expected in "same ballpark" as Q2, with mgmt assuming roughly 1x book-to-bill over the balance of the year, reflecting elevated cancels.
FX impact on revenue guidance change from April to today is "really neutral"; the guide change is fundamentally driven by an uptick in pass-throughs.
Burn rate expected broadly 8% for the year; Q3 may see slightly faster burn than Q4 due to pass-through activity from the COVID study.
Mgmt stance: Neutral — mgmt expects near-term cancellations to remain elevated but normalizing in Q4/next year; book-to-bill held at ~1x.
Q12 — Sebastian L. Sandler
Topic: China operations, licensing deals, and revenue exposure
Key points:
China revenue is approximately 3% (low single digits); ICON has about 1,200 people in China.
~1/3 of new global clinical trial starts are in China; Chinese biotechs use local CROs for domestic trials but turn to ICON for global trials (U.S./Europe registration).
ICON sees China as a medium- to longer-term fuel (3–5 years) for new compounds and licensing opportunities; has a strong BD team in China.
Mgmt stance: Bullish — mgmt is optimistic about China as a source of innovation, but emphasizes it is a longer-term play, not short-term.
Q13 — Michael Leonidovich Ryskin
Topic: Competitive environment and cost controls
Key points:
In large pharma, ICON competes with more established, global players; in biotech (especially early-phase), competition is more diversified, including niche/smaller CROs.
Cost controls: SG&A reduced $9M year-on-year; AI/bots deployed for routine work are driving down SG&A costs and improving efficiency.
Productivity and utilization improved on a broad basis year-over-year, helping both cost control and study delivery.
Mgmt stance: Bullish — mgmt is pleased with cost management, sees more to do, and views efficiency as a competitive advantage in pricing.